Supplemental Table 1

Parkinson’s disease medication changes at 1 year

|  |  |
| --- | --- |
| n (%) | All(N=122) |
| All regimensa stableb | 84 (68.9) |
| Any regimena with changes or additionsc | 38 (31.1) |
| Levodopa dose stable | 89 (73.0) |
| Levodopa dose changed | 33 (27.0) |
| Increase | 22 (66.7) |
| Decrease | 11 (33.3) |
| Dopamine agonists, baseline status = N | 47 |
| No change | 45 (95.7) |
| Started use | 2 (4.3) |
| Dopamine agonists, baseline status = Y | 75 |
| Continued use | 66 (88.0) |
| Discontinued use | 9 (12.0) |
| MAO Inhibitors, Baseline Status = N | 71 |
| No Change | 70 (98.6) |
| Started Use | 1 (1.4) |
| MAO inhibitors, baseline status = Y | 51 |
| Continued use | 49 (96.1) |
| Discontinued use | 2 (3.9) |
| Dopamine agonists, baseline status = N | 47 |
| No change | 45 (95.7) |
| Started use | 2 (4.3) |
| Dopamine agonists, baseline status = Y | 75 |
| Continued use | 66 (88.0) |
|  Discontinued use | 9 (12.0) |
| MAO inhibitors, baseline status = N | 71 |
|  No change | 70 (98.6) |
|  Started use | 1 (1.4) |
| MAO inhibitors, baseline status = Y | 51 |
| Continued use | 49 (96.1) |
|  Discontinued use | 2 (3.9) |

COMT, catechol-*O*-methyl transferase; MAO, monoamine oxidase; MDS-UPDRS, Movement Disorder Society–Unified Parkinson’s Disease Rating Scale. aParkinson's disease regimens are defined as levodopa, dopamine agonists, MAO inhibitors, COMT inhibitors, or anticholinergics. bA subject is stable if all baseline regimens remained unchanged at the week 52 MDS-UPDRS assessment date. cA subject is counted as 'change or addition' if any of the baseline regimens were discontinued by the week 52 MDS-UPDRS assessment date, a new baseline regimen medication was added by the week 52 MDS-UPDRS assessment date, or a completely new regimen was added by the week 52 MDS-UPDRS assessment date.